ZoomMed inc.

ZoomMed inc.

June 12, 2008 07:00 ET

ZoomMed Signs a Renewal Agreement With Boeringer Ingelheim

MONTREAL, QUEBEC--(Marketwire - June 12, 2008) - ZoomMed (TSX VENTURE:ZMD), developer of the "ZRx Prescriber" intended for physicians, is proud to announce that Boehringer Ingelheim, a pharmaceutical company, signed a renewal agreement, for the diffusion of information to physicians using the ZRx Prescriber.

"This renewal agreement with Boehringer Ingelheim, for a second consecutive year, proves that the ZRx Prescriber is a valuable and durable market solution, both from the technology and the market acceptance points of view. The ZRx Prescriber represents a direct way of accessing physicians in an effort to properly represent products, ability to post educational messages, compliance programs, etc." declared Mr. Yves Marmet, CEO of the Corporation.

Boehringer Ingelheim, headquartered in Ingelheim, Germany, has close to 37,500 employees and 143 affiliated companies spread around the globe. They are a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life.

About the ZRx Prescriber

The "ZRx Prescriber" is a Web application that runs on a pocket computer or a PC. The tool is used by physicians to fill out prescriptions and make them available to pharmacists, who can view them online via unique barcodes and confirm them using the physician's signed copy. Prescription errors (illegible handwriting, incorrect dosage, drug interactions) lead to 700 fatalities and 150,000 hospitalizations every year in Canada, representing $613 million in additional healthcare costs.

The "ZRx Prescriber" also gives physicians access to a portable source of medical information generated by the pharmaceutical companies and private or public organizations that use this revolutionary new communication tool. Thanks to the "ZRx Prescriber", thousands of Canadian physicians can now have access to vital information such as clinical studies, scientific discoveries, new product launches, medical training information and major medical alerts.

FOR FURTHER INFORMATION ON; Boehringer Ingelheim Canada, please visit the Web Site; www.boehringer-ingelheim.ca

FOR FURTHER INFORMATION ON; ZoomMed, the distribution and/or integration of the "ZRx Prescriber" to your solution, contact us through the following. You can also visit our Web Site; www.zoommed.com

The TSX Venture Exchange does not assume any responsibility for the adequacy or accuracy of this press release.

Contact Information

  • ZoomMed inc.
    Yves Marmet
    President and Chief Executive Officer
    450-678-5457, Ext 228